TY - JOUR
T1 - International photographic classification and grading system for myopic maculopathy
AU - Ohno-Matsui, Kyoko
AU - Kawasaki, Ryo
AU - Jonas, Jost B.
AU - Cheung, Chui Ming Gemmy
AU - Saw, Seang Mei
AU - Verhoeven, Virginie J.M.
AU - Klaver, Caroline C.W.
AU - Moriyama, Muka
AU - Shinohara, Kosei
AU - Kawasaki, Yumiko
AU - Yamazaki, Mai
AU - Meuer, Stacy
AU - Ishibashi, Tatsuro
AU - Yasuda, Miho
AU - Yamashita, Hidetoshi
AU - Sugano, Akira
AU - Wang, Jie Jin
AU - Mitchell, Paul
AU - Wong, Tien Yin
N1 - Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflict of Interest. Financial disclosures: Tien Y. Wong is a consultant for Novartis Pharma (Basel, Switzerland) and Bayer (Leverkusen, Germany); Kyoko Ohno-Matsui is a consultant for Bayer (Leverkusen, Germany); Ryo Kawasaki is a consultant for Office Future Inc (Tokyo, Japan); Jost B. Jonas is a consultant for Allergan Inc (Irvine, California), Merck Sharp & Dohme Co, Inc (Munchen, Germany), Alimera Co (Alpharetta, Georgia), Boehringer Ingelheim Co (Ingelheim, Germany), and Sanofi Co (Frankfurt, Germany) and is a patent holder with CellMed AG (Alzenau, Germany); Ryo Kawasaki had support for travel for the meeting of the present study from Novartis Pharma (Basel, Switzerland). Kyoko Ohno-Matsui has obtained research funding from the Japanese Society for Promotion of Science in Tokyo, Japan ( 22390322 and 25670729 ). Kyoko Ohno-Matsui and Ryo Kawasaki have obtained research funding from Novartis Pharma (Basel, Switzerland). The funding source had no influence on the interpretation or publication of the study. Contributions of authors: design of the study (R.K., K.O.M., J.B.J., S.M.S., V.J.M.V., C.C.W.K., J.J.W., P.M., T.Y.W.), conduct of the study (K.O.M., R.K., J.B.J., C.M.G.C., S.M.S., V.J.M.V., C.C.W.K., M.M., K.S., Y.K., M.Y., S.M., T.I., M.Y., H.Y., A.S., J.J.W., P.M., T.Y.W.), writing the article (R.K., K.O.M.), critical revision of the article (R.K., K.O.M., J.B.J., C.M.G.C., S.M.S., V.J.M.V., C.C.W.K., J.J.W., P.M., T.Y.W.), obtaining funding (R.K., K.O.M.), statistical expertise (R.K.), literature search (R.K., K.O.M.).
Publisher Copyright:
© 2015 by Elsevier Inc. All rights reserved.
PY - 2015/5/1
Y1 - 2015/5/1
N2 - Purpose To develop a classification and grading system for myopic maculopathy. Design Development and evaluation of a classification system for myopic maculopathy based on observational case series. Methods A comprehensive set of myopic macular lesions was defined via literature review and through consensus meetings among retinal specialists and clinician scientists. A classification of myopic maculopathy was formulated based on fundus photographs and a modified Delphi process and consensus. Inter- and intraobserver reproducibility, assessed as agreement (%) and weighted kappa values, were evaluated. One hundred retinal photographs with myopia and myopic macular lesions were selected from case series at the High Myopia Clinic of the Tokyo Medical and Dental University, Tokyo, Japan. Results We defined 5 categories of myopic maculopathy including "no myopic retinal degenerative lesion" (Category 0), "tessellated fundus" (Category 1), "diffuse chorioretinal atrophy" (Category 2), "patchy chorioretinal atrophy" (Category 3), and "macular atrophy" (Category 4). Three additional features to supplement these categories were defined as "plus" lesions, namely, lacquer cracks, myopic choroidal neovascularization, and Fuchs spot. Posterior staphyloma was considered as a further, important sign of myopic retinopathy. The intraobserver agreement was ≥85% and the corresponding weighted kappa statistic was ≥0.6 between observations. After a brief training session, interobserver kappa statistics reached the predefined satisfactory level (≥0.4), considered as above moderate agreement. Conclusions We propose a classification system for myopic maculopathy that was found to be reproducible. Applying a uniform classification in different studies will facilitate communication and comparison of findings from clinical trials and epidemiologic studies.
AB - Purpose To develop a classification and grading system for myopic maculopathy. Design Development and evaluation of a classification system for myopic maculopathy based on observational case series. Methods A comprehensive set of myopic macular lesions was defined via literature review and through consensus meetings among retinal specialists and clinician scientists. A classification of myopic maculopathy was formulated based on fundus photographs and a modified Delphi process and consensus. Inter- and intraobserver reproducibility, assessed as agreement (%) and weighted kappa values, were evaluated. One hundred retinal photographs with myopia and myopic macular lesions were selected from case series at the High Myopia Clinic of the Tokyo Medical and Dental University, Tokyo, Japan. Results We defined 5 categories of myopic maculopathy including "no myopic retinal degenerative lesion" (Category 0), "tessellated fundus" (Category 1), "diffuse chorioretinal atrophy" (Category 2), "patchy chorioretinal atrophy" (Category 3), and "macular atrophy" (Category 4). Three additional features to supplement these categories were defined as "plus" lesions, namely, lacquer cracks, myopic choroidal neovascularization, and Fuchs spot. Posterior staphyloma was considered as a further, important sign of myopic retinopathy. The intraobserver agreement was ≥85% and the corresponding weighted kappa statistic was ≥0.6 between observations. After a brief training session, interobserver kappa statistics reached the predefined satisfactory level (≥0.4), considered as above moderate agreement. Conclusions We propose a classification system for myopic maculopathy that was found to be reproducible. Applying a uniform classification in different studies will facilitate communication and comparison of findings from clinical trials and epidemiologic studies.
UR - http://www.scopus.com/inward/record.url?scp=84927546831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927546831&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2015.01.022
DO - 10.1016/j.ajo.2015.01.022
M3 - Article
C2 - 25634530
AN - SCOPUS:84927546831
SN - 0002-9394
VL - 159
SP - 877-883.e7
JO - American journal of ophthalmology
JF - American journal of ophthalmology
IS - 5
M1 - 9218
ER -